1 Apweiler, R., Hermjakob, H. & Sharon, N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 1473, 4-8, doi:10.1016/s0304-4165(99)00165-8 (1999).
2 Varki, A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 3, 97-130, doi:10.1093/glycob/3.2.97 (1993).
3 Kobata, A. Glycobiology: An expanding research area in carbohydrate chemistry. Acc. Chem. Res. 26, 319-324 (1993).
4 Bennett, E. P. et al. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22, 736-756, doi:10.1093/glycob/cwr182 (2012).
5 Ju, T., Brewer, K., D'Souza, A., Cummings, R. D. & Canfield, W. M. Cloning and expression of human core 1 beta1,3-galactosyltransferase. J Biol Chem 277, 178- 186, doi:10.1074/jbc.M109060200 (2002).
6 Ju, T. & Cummings, R. D. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A 99, 16613-16618, doi:10.1073/pnas.262438199 (2002).
7 Xia, L. et al. Defective angiogenesis and fatal embryonic hemorrhage in mice lacking core 1-derived O-glycans. The Journal of cell biology 164, 451-459, doi:10.1083/jcb.200311112 (2004).
8 Wang, Y. et al. Cosmc is an essential chaperone for correct protein O-glycosylation. Proc Natl Acad Sci U S A 107, 9228-9233, doi:10.1073/pnas.0914004107 (2010).
9 Mi, R. et al. Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing Tn antigen. J Biol Chem 287, 41523-41533, doi:10.1074/jbc.M112.371989 (2012).
10 Ju, T., Zheng, Q. & Cummings, R. D. Identification of core 1 O-glycan T-synthase from Caenorhabditis elegans. Glycobiology 16, 947-958, doi:10.1093/glycob/cwl008 (2006).
11 Ju, T., Aryal, R. P., Stowell, C. J. & Cummings, R. D. Regulation of protein O- glycosylation by the endoplasmic reticulum-localized molecular chaperone Cosmc. The Journal of cell biology 182, 531-542, doi:10.1083/jcb.200711151 (2008).
12 Berger, E. G. Tn-syndrome. Biochim Biophys Acta 1455, 255-268, doi:10.1016/s0925-4439(99)00069-1 (1999).
13 Ju, T. & Cummings, R. D. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 437, 1252, doi:10.1038/4371252a (2005).
14 Crew, V. K. et al. New mutations in C1GALT1C1 in individuals with Tn positive phenotype. Br J Haematol 142, 657-667, doi:10.1111/j.1365-2141.2008.07215.x (2008).
15 Gupta, R., Leon, F., Rauth, S., Batra, S. K. & Ponnusamy, M. P. A Systematic Review on the Implications of O-linked Glycan Branching and Truncating Enzymes on Cancer Progression and Metastasis. Cells 9, doi:10.3390/cells9020446 (2020).
16 Ju, T. et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res 68, 1636-1646, doi:10.1158/0008-5472.CAN-07-2345 (2008).
17 D'Amico, G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 36, 227-237, doi:10.1053/ajkd.2000.8966 (2000).
18 Lehoux, S. et al. Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals. Mol Cell Proteomics 13, 3097-3113, doi:10.1074/mcp.M114.039693 (2014).
19 Inoue, T. et al. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol 136, 447-455, doi:10.1016/j.clim.2010.05.009 (2010).
20 Yamada, K. et al. Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant 25, 3890-3897, doi:10.1093/ndt/gfq325 (2010).
21 Alexander, W. S. et al. Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. Proc Natl Acad Sci U S A 103, 16442-16447, doi:10.1073/pnas.0607872103 (2006).
22 Kudo, T. et al. C1galt1-deficient mice exhibit thrombocytopenia due to abnormal terminal differentiation of megakaryocytes. Blood 122, 1649-1657, doi:10.1182/blood-2012-12-471102 (2013).
23 Asanuma, K. & Mundel, P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 7, 255-259, doi:10.1007/s10157-003-0259-6 (2003).
24 Putaala, H., Soininen, R., Kilpelainen, P., Wartiovaara, J. & Tryggvason, K. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 10, 1-8, doi:10.1093/hmg/10.1.1 (2001).
25 Jeansson, M. & Haraldsson, B. Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycan-degrading enzymes. J Am Soc Nephrol 14, 1756-1765, doi:10.1097/01.asn.0000072742.02714.6e (2003).
26 Aoki, S. et al. The reduction of heparan sulphate in the glomerular basement membrane does not augment urinary albumin excretion. Nephrol Dial Transplant 33, 26-33, doi:10.1093/ndt/gfx218 (2018).
27 Wakui, H. et al. Incomplete clearance of apoptotic cells by core 1-derived O-glycan- deficient resident peritoneal macrophages. Biochemical and biophysical research communications 495, 2017-2023, doi:10.1016/j.bbrc.2017.12.066 (2018).
28 Yokoi, H. et al. Podocyte-specific expression of tamoxifen-inducible Cre recombinase in mice. Nephrol Dial Transplant 25, 2120-2124, doi:10.1093/ndt/gfq029 (2010).
29 Ichimura, K. et al. Podocalyxin regulates pronephric glomerular development in zebrafish. Physiol Rep 1, doi:10.1002/phy2.74 (2013).
30 Takemoto, M. et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161, 799-805, doi:10.1016/S0002-9440(10)64239-3 (2002).
31 Debruin, E. J. et al. Podocalyxin regulates murine lung vascular permeability by altering endothelial cell adhesion. PLoS One 9, e108881, doi:10.1371/journal.pone.0108881 (2014).
32 Nielsen, J. S. & McNagny, K. M. Novel functions of the CD34 family. J Cell Sci 121, 3683-3692, doi:10.1242/jcs.037507 (2008).
33 Orlando, R. A. et al. The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin. J Am Soc Nephrol 12, 1589-1598, doi:10.1681/ASN.V1281589 (2001).
34 Doyonnas, R. et al. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 194, 13-27, doi:10.1084/jem.194.1.13 (2001).
35 Kang, H. G. et al. Loss of podocalyxin causes a novel syndromic type of congenital nephrotic syndrome. Exp Mol Med 49, e414, doi:10.1038/emm.2017.227 (2017).
36 Refaeli, I. et al. Distinct Functional Requirements for Podocalyxin in Immature and Mature Podocytes Reveal Mechanisms of Human Kidney Disease. Sci Rep 10, 9419, doi:10.1038/s41598-020-64907-3 (2020).
37 Faul, C., Asanuma, K., Yanagida-Asanuma, E., Kim, K. & Mundel, P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 17, 428-437, doi:10.1016/j.tcb.2007.06.006 (2007).
38 Takeda, T., McQuistan, T., Orlando, R. A. & Farquhar, M. G. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 108, 289-301, doi:10.1172/JCI12539 (2001).
39 Schmieder, S., Nagai, M., Orlando, R. A., Takeda, T. & Farquhar, M. G. Podocalyxin activates RhoA and induces actin reorganization through NHERF1 and Ezrin in MDCK cells. J Am Soc Nephrol 15, 2289-2298, doi:10.1097/01.ASN.0000135968.49899.E8 (2004).
40 Fukasawa, H. et al. Phosphorylation of podocalyxin (Ser415) Prevents RhoA and ezrin activation and disrupts its interaction with the actin cytoskeleton. Am J Pathol 179, 2254-2265, doi:10.1016/j.ajpath.2011.07.046 (2011).
41 Marx, D. et al. Atypical focal segmental glomerulosclerosis associated with a new PODXL nonsense variant. Mol Genet Genomic Med 9, e1658, doi:10.1002/mgg3.1658 (2021).
42 Nielsen, J. S. et al. The CD34-related molecule podocalyxin is a potent inducer of microvillus formation. PLoS One 2, e237, doi:10.1371/journal.pone.0000237 (2007).
43 Shurer, C. R. et al. Physical Principles of Membrane Shape Regulation by the Glycocalyx. Cell 177, 1757-1770 e1721, doi:10.1016/j.cell.2019.04.017 (2019).
44 Fernandez, D. et al. Release of podocalyxin into the extracellular space. Role of metalloproteinases. Biochim Biophys Acta 1813, 1504-1510, doi:10.1016/j.bbamcr.2011.05.009 (2011).
45 Barisoni, L., Schnaper, H. W. & Kopp, J. B. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2, 529-542, doi:10.2215/CJN.04121206 (2007).
46 Rosenberg, A. Z. & Kopp, J. B. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 12, 502-517, doi:10.2215/CJN.05960616 (2017).
47 Pollak, M. R. Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint. J Am Soc Nephrol 13, 3016-3023, doi:10.1097/01.asn.0000039569.34360.5e (2002).
48 Pollak, M. R. Familial FSGS. Adv Chronic Kidney Dis 21, 422-425, doi:10.1053/j.ackd.2014.06.001 (2014).
49 Barua, M. et al. Exome sequencing and in vitro studies identified podocalyxin as a candidate gene for focal and segmental glomerulosclerosis. Kidney Int 85, 124-133, doi:10.1038/ki.2013.354 (2014).
50 Lin, F. J. et al. First identification of PODXL nonsense mutations in autosomal dominant focal segmental glomerulosclerosis. Clin Sci (Lond) 133, 9-21, doi:10.1042/CS20180676 (2019).
51 Song, K. et al. Loss of mucin-type O-glycans impairs the integrity of the glomerular filtration barrier in the mouse kidney. J Biol Chem 292, 16491-16497, doi:10.1074/jbc.M117.798512 (2017).
52 Stotter, B. R. et al. Cosmc-dependent mucin-type O-linked glycosylation is essential for podocyte function. Am J Physiol Renal Physiol 318, F518-F530, doi:10.1152/ajprenal.00399.2019 (2020).
53 Niculovic, K. M. et al. Podocyte-Specific Sialylation-Deficient Mice Serve as a Model for Human FSGS. J Am Soc Nephrol 30, 1021-1035, doi:10.1681/ASN.2018090951 (2019).
54 Wiggins, R. C. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71, 1205-1214, doi:10.1038/sj.ki.5002222 (2007).
55 Kuppe, C. et al. Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions. Kidney Int 96, 80-93, doi:10.1016/j.kint.2019.01.037 (2019).
56 Kitano, M. et al. Rab11-mediated post-Golgi transport of the sialyltransferase ST3GAL4 suggests a new mechanism for regulating glycosylation. J Biol Chem 296, 100354, doi:10.1016/j.jbc.2021.100354 (2021).
57 Mueller-Deile, J. et al. Podocalyxin-positive glomerular epithelial cells in urine correlate with a positive outcome in FSGS. J Nephrol 25, 802-809, doi:10.5301/jn.5000068 (2012).
58 Shoji, M., Kobayashi, K., Takemoto, M., Sato, Y. & Yokote, K. Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabetes. Biomarkers 21, 164-167, doi:10.3109/1354750X.2015.1118551 (2016).
59 Suwanpen, C. et al. Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity. J Nephrol 29, 37-44, doi:10.1007/s40620-015-0199-8 (2016).
60 Kwon, S. H. et al. Elevated urinary podocyte-derived extracellular microvesicles in renovascular hypertensive patients. Nephrol Dial Transplant 32, 800-807, doi:10.1093/ndt/gfw077 (2017).
61 Ikuma, D. et al. The correlation of urinary podocytes and podocalyxin with histological features of lupus nephritis. Lupus 27, 484-493, doi:10.1177/0961203317734918 (2018).
62 Cait, J. et al. Podocalyxin is required for maintaining blood-brain barrier function during acute inflammation. Proc Natl Acad Sci U S A 116, 4518-4527, doi:10.1073/pnas.1814766116 (2019).